1 | 10488091 | The ARF-like 2 (ARL2)-binding protein, BART. Purification, cloning, and initial characterization. | J Biol Chem | 1999 Sep 24 |
4 |
2 | 10683446 | A conserved small GTP-binding protein Alp41 is essential for the cofactor-dependent biogenesis of microtubules in fission yeast. | FEBS Lett | 2000 Feb 18 |
1 |
3 | 10831612 | ADP ribosylation factor-like protein 2 (Arl2) regulates the interaction of tubulin-folding cofactor D with native tubulin. | J Cell Biol | 2000 May 29 |
2 |
4 | 11980706 | The complex of Arl2-GTP and PDE delta: from structure to function. | EMBO J | 2002 May 1 |
1 |
5 | 12527357 | Photoreceptor synaptic protein HRG4 (UNC119) interacts with ARL2 via a putative conserved domain. | FEBS Lett | 2003 Jan 16 |
1 |
6 | 16413291 | Assays used in the analysis of Arl2 and its binding partners. | Methods Enzymol | 2005 |
1 |
7 | 17651460 | Mitochondrial DNA deletions induce the adenosine monophosphate-activated protein kinase energy stress pathway and result in decreased secretion of some proteins. | Aging Cell | 2007 Oct |
3 |
8 | 18818514 | Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. | Cell Cycle | 2008 Oct |
4 |
9 | 19636941 | 1H, 13C and 15N resonance assignments for Binder of Arl2, BART. | Biomol NMR Assign | 2009 Jun |
3 |
10 | 21319207 | Synthesis and biological evaluation of 2'-oxo-2,3-dihydro-3'H- spiro[chromene-4,5'-[1,3]oxazolidin]-3'yl]acetic acid derivatives as aldose reductase inhibitors. | Arch Pharm (Weinheim) | 2011 Jun |
4 |
11 | 21833473 | BART inhibits pancreatic cancer cell invasion by inhibiting ARL2-mediated RhoA inactivation. | Int J Oncol | 2011 Nov |
6 |
12 | 22002721 | Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. | Nat Chem Biol | 2011 Oct 16 |
1 |
13 | 22436396 | Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step. | Eur J Med Chem | 2012 May |
1 |
14 | 23807224 | MicroRNA-195 targets ADP-ribosylation factor-like protein 2 to induce apoptosis in human embryonic stem cell-derived neural progenitor cells. | Cell Death Dis | 2013 Jun 27 |
4 |
15 | 24911211 | The ARL2 GTPase is required for mitochondrial morphology, motility, and maintenance of ATP levels. | PLoS One | 2014 |
2 |
16 | 25550383 | Membrane protein transport in photoreceptors: the function of PDEδ: the Proctor lecture. | Invest Ophthalmol Vis Sci | 2014 Dec 30 |
2 |
17 | 26208336 | Tubulin cofactors and Arl2 are cage-like chaperones that regulate the soluble αβ-tubulin pool for microtubule dynamics. | Elife | 2015 Jul 24 |
2 |
18 | 26488653 | Effect of the N-Terminal Helix and Nucleotide Loading on the Membrane and Effector Binding of Arl2/3. | Biophys J | 2015 Oct 20 |
1 |
19 | 27806215 | Sorting of lipidated cargo by the Arl2/Arl3 system. | Small GTPases | 2016 Oct |
1 |
20 | 28137948 | Revisiting the tubulin cofactors and Arl2 in the regulation of soluble αβ-tubulin pools and their effect on microtubule dynamics. | Mol Biol Cell | 2017 Feb 1 |
1 |
21 | 28970104 | Nucleotide Binding to ARL2 in the TBCD∙ARL2∙β-Tubulin Complex Drives Conformational Changes in β-Tubulin. | J Mol Biol | 2017 Nov 24 |
2 |
22 | 29265919 | MicroRNA-497-5p Suppresses Tumor Cell Growth of Osteosarcoma by Targeting ADP Ribosylation Factor-Like Protein 2. | Cancer Biother Radiopharm | 2017 Dec |
3 |
23 | 29961325 | Arl2-Mediated Allosteric Release of Farnesylated KRas4B from Shuttling Factor PDEδ. | J Phys Chem B | 2018 Aug 2 |
4 |
24 | 30945270 | Whole-exome sequencing identified ARL2 as a novel candidate gene for MRCS (microcornea, rod-cone dystrophy, cataract, and posterior staphyloma) syndrome. | Clin Genet | 2019 Jul |
1 |
25 | 31858533 | MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2. | Eur Rev Med Pharmacol Sci | 2019 Dec |
1 |
26 | 33061617 | Circ_0084927 Facilitates Cervical Cancer Development via Sponging miR-142-3p and Upregulating ARL2. | Cancer Manag Res | 2020 |
4 |
27 | 33270982 | miR-15a-5p and miR-21-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. | J Cell Mol Med | 2021 Jan |
1 |